PL374544A1 - Związki imidazo-skondensowane - Google Patents
Związki imidazo-skondensowaneInfo
- Publication number
- PL374544A1 PL374544A1 PL03374544A PL37454403A PL374544A1 PL 374544 A1 PL374544 A1 PL 374544A1 PL 03374544 A PL03374544 A PL 03374544A PL 37454403 A PL37454403 A PL 37454403A PL 374544 A1 PL374544 A1 PL 374544A1
- Authority
- PL
- Poland
- Prior art keywords
- fused compounds
- imidazo
- imidazo fused
- compounds
- fused
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36992902P | 2002-04-03 | 2002-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL374544A1 true PL374544A1 (pl) | 2005-10-31 |
Family
ID=28675587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL03374544A PL374544A1 (pl) | 2002-04-03 | 2003-03-27 | Związki imidazo-skondensowane |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US6949560B2 (pl) |
| EP (1) | EP1492790A1 (pl) |
| JP (1) | JP2006503802A (pl) |
| KR (1) | KR100656205B1 (pl) |
| CN (1) | CN1293078C (pl) |
| AR (1) | AR039219A1 (pl) |
| AU (1) | AU2003215675B2 (pl) |
| BR (1) | BR0308937A (pl) |
| CA (1) | CA2479644A1 (pl) |
| MX (1) | MXPA04009585A (pl) |
| PL (1) | PL374544A1 (pl) |
| RU (1) | RU2310657C2 (pl) |
| WO (1) | WO2003082871A1 (pl) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050070554A1 (en) * | 2003-08-27 | 2005-03-31 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| DE10361659A1 (de) | 2003-12-30 | 2005-07-28 | Osram Opto Semiconductors Gmbh | Verfahrem zum Herstellen einer epitaktischen Bauelementschichtenfolge und optoelektronischer Halbleiterchip |
| FR2873118B1 (fr) * | 2004-07-15 | 2007-11-23 | Sanofi Synthelabo | Derives de pyrido-pyrimidine, leur application en therapeutique |
| US20100104536A1 (en) * | 2007-03-20 | 2010-04-29 | Indravadan Ambalal Modi | P38 inhibitors |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| CA2851801A1 (en) * | 2011-10-21 | 2013-04-25 | Glaxosmithkline Llc | Compounds and methods for enhancing innate immune responses |
| RS58514B1 (sr) | 2012-06-13 | 2019-04-30 | Incyte Holdings Corp | Supstituisana triciklična jedinjenja kao inhibitori fgfr |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| CN105481858B (zh) * | 2014-10-11 | 2019-05-17 | 上海医药集团股份有限公司 | 一种含氮稠杂环化合物、其制备方法、组合物及应用 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| TWI712601B (zh) | 2015-02-20 | 2020-12-11 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| EP3368052B1 (en) | 2015-10-27 | 2021-12-08 | Children's Hospital Medical Center | Use of mapk inhibitors to reduce loss of hematopoietic stem cells during ex vivo culture and genetic manipulation |
| US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
| KR20180002053A (ko) * | 2016-06-28 | 2018-01-05 | 한미약품 주식회사 | 신규한 헤테로시클릭 유도체 화합물 및 이의 용도 |
| WO2018004258A1 (ko) * | 2016-06-28 | 2018-01-04 | 한미약품 주식회사 | 신규한 헤테로시클릭 유도체 화합물 및 이의 용도 |
| US10703759B2 (en) * | 2016-11-16 | 2020-07-07 | Impact Therapeutics, Inc | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones |
| US11365196B2 (en) | 2017-02-27 | 2022-06-21 | Betta Pharmaceuticals Co., Ltd. | FGFR inhibitor and application thereof |
| CN109923115B (zh) * | 2017-05-23 | 2021-06-01 | 晟科药业（江苏）有限公司 | 咪唑并[1’,2’:1,6]吡啶并[2,3-d]嘧啶类化合物作为蛋白激酶抑制剂 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| BR112020006677A2 (pt) | 2017-10-05 | 2020-10-06 | Fulcrum Therapeutics, Inc. | uso de inibidores p38 para reduzir a expressão de dux4 |
| US11267815B2 (en) | 2017-10-30 | 2022-03-08 | Shanghai Ringene Biopharma Co., Ltd. | Class of amino-substituted nitrogen-containing fused ring compounds, preparation method therefor, and use thereof |
| WO2019085894A1 (zh) * | 2017-10-30 | 2019-05-09 | 如东凌达生物医药科技有限公司 | 一类含氮稠环化合物及其制备方法和用途 |
| HRP20241288T1 (hr) | 2018-05-04 | 2024-12-06 | Incyte Corporation | Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju |
| AU2019262579B2 (en) | 2018-05-04 | 2024-09-12 | Incyte Corporation | Salts of an FGFR inhibitor |
| CN110857300B (zh) * | 2018-08-23 | 2021-11-05 | 上海凌达生物医药有限公司 | 一类稠环三氮唑类化合物、制备方法和用途 |
| CN112654623B (zh) * | 2018-08-27 | 2023-05-23 | 贝达药业股份有限公司 | 新型氮杂三环类化合物的盐型、晶型及其用途 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| US20220185811A1 (en) * | 2019-03-08 | 2022-06-16 | Shouyao Holdings (beijing) Co., Ltd. | Fgfr4 kinase inhibitor and preparation method therefor and use thereof |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CA3150681A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US11851426B2 (en) | 2019-10-11 | 2023-12-26 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| CA3157361A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP7832891B2 (ja) | 2019-12-04 | 2026-03-18 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の誘導体 |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| KR20230112605A (ko) * | 2020-08-07 | 2023-07-27 | 에이비엠 쎄라퓨틱스 코포레이션 | 키나아제 억제제 및 그의 용도 |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522947A (en) | 1982-03-29 | 1985-06-11 | Usv Pharmaceutical Corporation | Certain 1,3-oxazolo[4,5H]quinolines useful as anti-allergy agents |
| US4656281A (en) | 1983-03-18 | 1987-04-07 | Usv Pharmaceutical Corp. | Imidazo quinoline compounds useful as anti-allergy agents |
| DE3502689A1 (de) | 1985-01-26 | 1986-07-31 | Hoechst Ag, 6230 Frankfurt | Elektrophotographisches aufzeichnungsmaterial |
| US4831040A (en) | 1988-02-01 | 1989-05-16 | Rorer Pharmaceutical Corporation | Method of prevention and treatment of peptic ulcers |
| GB9123916D0 (en) | 1991-11-11 | 1992-01-02 | Wellcome Found | Heterocyclic compounds |
| DE19510965A1 (de) * | 1995-03-24 | 1996-09-26 | Asta Medica Ag | Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung |
| JPH11292878A (ja) | 1998-04-09 | 1999-10-26 | Yamanouchi Pharmaceut Co Ltd | イミダゾナフチリジン誘導体 |
| AU776250B2 (en) * | 1999-10-21 | 2004-09-02 | F. Hoffmann-La Roche Ag | Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase |
| CA2420286A1 (en) * | 2000-08-31 | 2002-03-07 | F. Hoffmann-La Roche Ag | 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation |
| DE60206363T2 (de) | 2001-02-12 | 2006-07-06 | F. Hoffmann-La Roche Ag | 6-substituierte pyridopyrimidine |
-
2003
- 2003-03-27 JP JP2003580336A patent/JP2006503802A/ja active Pending
- 2003-03-27 EP EP03745276A patent/EP1492790A1/en not_active Withdrawn
- 2003-03-27 WO PCT/EP2003/003178 patent/WO2003082871A1/en not_active Ceased
- 2003-03-27 PL PL03374544A patent/PL374544A1/pl not_active Application Discontinuation
- 2003-03-27 RU RU2004132204/04A patent/RU2310657C2/ru active
- 2003-03-27 MX MXPA04009585A patent/MXPA04009585A/es active IP Right Grant
- 2003-03-27 CN CNB038075369A patent/CN1293078C/zh not_active Expired - Fee Related
- 2003-03-27 BR BR0308937-1A patent/BR0308937A/pt not_active IP Right Cessation
- 2003-03-27 CA CA002479644A patent/CA2479644A1/en not_active Abandoned
- 2003-03-27 AU AU2003215675A patent/AU2003215675B2/en not_active Ceased
- 2003-03-27 KR KR1020047015609A patent/KR100656205B1/ko not_active Expired - Fee Related
- 2003-04-02 AR ARP030101141A patent/AR039219A1/es unknown
- 2003-04-03 US US10/406,364 patent/US6949560B2/en not_active Expired - Fee Related
-
2005
- 2005-05-04 US US11/122,137 patent/US7081462B2/en not_active Expired - Fee Related
-
2006
- 2006-07-13 US US11/486,348 patent/US7285561B2/en not_active Expired - Fee Related
- 2006-07-13 US US11/486,193 patent/US7285559B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20060252783A1 (en) | 2006-11-09 |
| MXPA04009585A (es) | 2005-01-11 |
| CN1646529A (zh) | 2005-07-27 |
| BR0308937A (pt) | 2005-01-04 |
| RU2310657C2 (ru) | 2007-11-20 |
| RU2004132204A (ru) | 2005-11-20 |
| WO2003082871A1 (en) | 2003-10-09 |
| JP2006503802A (ja) | 2006-02-02 |
| US6949560B2 (en) | 2005-09-27 |
| KR100656205B1 (ko) | 2006-12-12 |
| EP1492790A1 (en) | 2005-01-05 |
| CA2479644A1 (en) | 2003-10-09 |
| KR20040099384A (ko) | 2004-11-26 |
| CN1293078C (zh) | 2007-01-03 |
| AR039219A1 (es) | 2005-02-09 |
| US20050197352A1 (en) | 2005-09-08 |
| US7285561B2 (en) | 2007-10-23 |
| AU2003215675B2 (en) | 2007-07-12 |
| US7285559B2 (en) | 2007-10-23 |
| US20030232847A1 (en) | 2003-12-18 |
| US20060252784A1 (en) | 2006-11-09 |
| US7081462B2 (en) | 2006-07-25 |
| AU2003215675A1 (en) | 2003-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL374544A1 (pl) | Związki imidazo-skondensowane | |
| PT2042504E (pt) | Derivados da azolepirimidina fundida | |
| HUS1600008I1 (hu) | Cefémvegyületek | |
| HRP20041166A2 (en) | Carbamate-substituted pyrazolopyridines | |
| EP1687002A4 (en) | CONDENSED HETEROCYCLIC COMPOUNDS | |
| IL174283A0 (en) | Fused heterocyclic compounds | |
| EP1558585A4 (en) | NEUROLOGICALLY ACTIVE COMPOUNDS | |
| EP1569644A4 (en) | INDOLIZINE COMPOUNDS | |
| GB0200283D0 (en) | Compounds | |
| IL176384A0 (en) | Novel fused pyrrolocarbazoles | |
| MY142713A (en) | Novel fused pyrrolocarbazoles | |
| PL372989A1 (pl) | Triazolopirymidyny | |
| PL376659A1 (pl) | Skondensowane związki heterocykliczne | |
| AU2003216859A8 (en) | Amidoacetonitrile compounds | |
| IL161836A0 (en) | Aryl fused azapolycyclic compounds | |
| GB0207323D0 (en) | Compounds | |
| GB0203778D0 (en) | Compounds | |
| AU2003275480A8 (en) | Compounds | |
| GB0203811D0 (en) | Compounds | |
| GB0217850D0 (en) | Fused socket | |
| GB0206981D0 (en) | Compounds | |
| GB0207270D0 (en) | Compounds | |
| AU2003274754A8 (en) | Cephem compounds | |
| GB0203807D0 (en) | Compounds | |
| GB0203900D0 (en) | Compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |